Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
azelastine + fluticasone propionate (Viatris)
- Development stage
- Phase 4
- Lead developer
- Viatris
- Modality
- Small Molecules
- Administration
- Intranasal
01
Overview
Flutiaze is a combination nasal spray containing azelastine hydrochloride (an antihistamine) and fluticasone propionate (a corticosteroid). Developed by Getz Pharma as a generic version of Dymista, it is indicated for the symptomatic relief of seasonal and perennial allergic rhinitis in adults and pediatric patients. Azelastine works by blocking histamine H1 receptors and stabilizing mast cells to rapidly alleviate symptoms like sneezing, itching, and runny nose. Fluticasone propionate is a potent glucocorticoid receptor agonist that reduces inflammation, swelling, and mucus production in the nasal passages. Together, the two active ingredients provide rapid and synergistic relief from nasal allergy symptoms.
- Brand names
- Flutiaze
- Other names
- azelastine hydrochloride + fluticasone propionateazelastine hydrochloride/fluticasone propionateazelastine/fluticasoneazelastine/fluticasone propionate
02
Targets
GR (Glucocorticoid receptor)HRH1 (Histamine H1 Receptor)HRH2 (Histamine H2 Receptor)PR (Progesterone receptor)
Beyond the preview
Go deeper on azelastine + fluticasone propionate (Viatris).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on azelastine + fluticasone propionate (Viatris).